DEX Stock Overview
Engages in the development of drug candidates with application in urological oncology, primarily prostate cancer.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Dextech Medical AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr4.10 |
| 52 Week High | kr7.40 |
| 52 Week Low | kr3.70 |
| Beta | 1.5 |
| 1 Month Change | -5.53% |
| 3 Month Change | -34.92% |
| 1 Year Change | -18.33% |
| 3 Year Change | -88.64% |
| 5 Year Change | -94.94% |
| Change since IPO | -59.00% |
Recent News & Updates
Recent updates
Dextech Medical (NGM:DEX) Is In A Good Position To Deliver On Growth Plans
Jan 10
Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth
Sep 20We're Not Very Worried About Dextech Medical's (NGM:DEX) Cash Burn Rate
Jun 03What Kind Of Shareholders Hold The Majority In Dextech Medical AB's (NGM:DEX) Shares?
Feb 17
Companies Like Dextech Medical (NGM:DEX) Are In A Position To Invest In Growth
Dec 12Shareholder Returns
| DEX | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -1.9% | -2.6% | -2.1% |
| 1Y | -18.3% | 3.0% | 11.2% |
Return vs Industry: DEX underperformed the Swedish Biotechs industry which returned 3% over the past year.
Return vs Market: DEX underperformed the Swedish Market which returned 11.2% over the past year.
Price Volatility
| DEX volatility | |
|---|---|
| DEX Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.7% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: DEX's share price has been volatile over the past 3 months.
Volatility Over Time: DEX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 1 | Anders Holmberg | www.dextechmedical.com |
Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer. Its principal product candidate is OsteoDex that has completed phase IIb clinical trial for the treatment of skeletal metastases in castration resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is based on an endogenous hormone, somatostatin, to treat acromegaly, neuroendocrine tumors, and palliative treatment for advanced prostate cancer; and PSMA-binding conjugates for the target-specific treatment of mCRPC that overexpresses prostate specific membrane antigen (PSMA).
Dextech Medical AB Fundamentals Summary
| DEX fundamental statistics | |
|---|---|
| Market cap | kr75.79m |
| Earnings (TTM) | -kr4.53m |
| Revenue (TTM) | kr5.43m |
13.9x
P/S Ratio-16.7x
P/E RatioIs DEX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DEX income statement (TTM) | |
|---|---|
| Revenue | kr5.43m |
| Cost of Revenue | kr23.00k |
| Gross Profit | kr5.41m |
| Other Expenses | kr9.94m |
| Earnings | -kr4.53m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 30, 2024
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 99.58% |
| Net Profit Margin | -83.30% |
| Debt/Equity Ratio | 0% |
How did DEX perform over the long term?
See historical performance and comparison